Login to Your Account

Clinic Roundup

Monday, August 13, 2012

• Genentech Inc., a South San Francisco-based member of the Roche Group, reported that Avastin (bevacizumab) plus radiation and temozolomide chemotherapy demonstrated a significant improvement in progression-free survival, a co-primary endpoint of the Phase III AVAglio study.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription